A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

被引：0
|
作者：
Milan Zdravkovic
Anette K. Olsen
Tina Christiansen
Rainer Schulz
Mitchell E. Taub
Mikael S. Thomsen
Michael H. Rasmussen
Mapoko M. Ilondo
机构：
[1] Research and Development,Novo Nordisk A/S
[2] Department of Clinical Drug Development,Novo Nordisk A/S
[3] Quintiles Innovex (Biodesign),undefined
来源：
European Journal of Clinical Pharmacology | 2003年 / 58卷
关键词：
CYP3A4; Interaction; Midazolam; NN703; Clinical study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：683 / 688
页数：5
相关论文
共 50 条
  • [1] A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
    Zdravkovic, M
    Olsen, AK
    Christiansen, T
    Schulz, R
    Taub, ME
    Thomsen, MS
    Rasmussen, MH
    Ilondo, MM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (10) : 683 - 688
  • [2] Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity
    Mikus, Gerd
    Foerster, Kathrin Isabelle
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1592 - S1599
  • [3] Lack of a pharmacokinetic interaction between escitalopram and the CYP3A4 inhibitor ritonavir
    Gutierrez, M
    Abramowitz, W
    BIOLOGICAL PSYCHIATRY, 2001, 49 (08) : 51S - 51S
  • [4] Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study
    Callegari, Ernesto
    Tse, Susanna
    Doran, Angela C.
    Goosen, Theunis C.
    Shaik, Naveed
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (01): : 80 - 93
  • [5] A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
    Pierre-Eric Juif
    Margaux Boehler
    Yves Donazzolo
    Shirin Bruderer
    Jasper Dingemanse
    European Journal of Clinical Pharmacology, 2017, 73 : 1121 - 1128
  • [6] Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
    Miller, Claire
    Sommavilla, Roberto
    O'Bryant, Cindy L.
    Barve, Minal
    Dowlati, Afshin
    Luke, Jason J.
    Khatun, Mahmuda
    Morris, Thomas
    Cullberg, Marie
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 223 - 235
  • [7] Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam
    Toth, Maria
    Drabant, Sandor
    Varga, Balint
    Vegso, Gyula
    Cseh, Anna
    Szentpeteri, Imre
    Klebovich, Imre
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (01) : 93 - 94
  • [8] Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam
    Mária Tóth
    Sándor Drabant
    Bálint Varga
    Gyula Végső
    Anna Cseh
    Imre Szentpéteri
    Imre Klebovich
    European Journal of Clinical Pharmacology, 2008, 64 : 93 - 94
  • [9] A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
    Juif, Pierre-Eric
    Boehler, Margaux
    Donazzolo, Yves
    Bruderer, Shirin
    Dingemanse, Jasper
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (09) : 1121 - 1128
  • [10] Lack of interaction between citalopram and the CYP3A4 substrate triazolam
    Nolting, A
    Abramowitz, W
    PHARMACOTHERAPY, 2000, 20 (07): : 750 - 755
12345